Melanoma: Related News

On Our Blog

Pictured: Anna Skripnik & Kathryn Ciccollini
Spotlight on Dermatology Nursing

Today, we spotlight our dermatology nurses. Learn more about them.

July 25, 2014
Five Questions for Sarcoma and Melanoma Expert Mark Dickson

In this Q&A and video, medical oncologist Mark Dickson discusses his approach to treating sarcoma and melanoma and how he develops individual treatment plans for each patient.

July 21, 2014
Pictured: Jedd Wolchok
Memorial Sloan Kettering’s Expertise in Cancer Immunotherapy Draws Media Focus at 2014 ASCO Meeting

Our experts offer their perspective in major media outlets on recent research into drug- and cell-based immunotherapies for cancer.

June 4, 2014
Pictured: Jedd Wolchok & Alexander Rudensky
Memorial Sloan Kettering Shares Historic Gift to Fund Immunotherapy Research

Immunologist Alexander Rudensky and medical oncologist and immunologist Jedd Wolchok are investigating innovative ways to use the immune system to fight cancer.

January 6, 2014
Pictured: T cells
Cancer Immunotherapy Named Science Magazine “Breakthrough of the Year”

Memorial Sloan Kettering researchers have played a major role in cancer immunotherapy research, named “Breakthrough of the Year” by Science magazine.

December 23, 2013
Pictured: Sandra D’Angelo
Meet Medical Oncologist Sandra D’Angelo

Medical oncologist Sandra D’Angelo, who specializes in caring for patients with rare cancers such as melanoma, soft tissue sarcoma, and Merkel cell carcinoma, talks about the team approach and the importance of empowering patients.

March 21, 2014
Pictured: Steven Wang
What Should a Person Look for on a Sunscreen Label?

In this “Ask the Expert” feature, dermatologist Steven Wang discusses how to choose the most effective sunscreen.

May 15, 2013
Pictured: Jedd Wolchok & Richard Carvajal
Memorial Sloan Kettering Researchers Report on Major Advances in the Treatment of Metastatic Eye and Skin Melanoma

Two Memorial Sloan Kettering studies that hold promise for the treatment of advanced uveal (eye) melanoma and advanced skin melanoma are making headlines at the 49th Annual Meeting of the American Society of Clinical Oncology.

June 3, 2013
Pictured: Melanocytes
Pigment-Producing Skin Cells Generated Using Stem Cell Technology

Memorial Sloan Kettering researchers have developed innovative ways to study some skin diseases, including melanoma skin cancer.

May 14, 2013
Pictured: Liang Deng
At Work: Physician-Scientist Liang Deng

Physician-scientist Liang Deng cares for patients with melanoma and other skin cancers, and also conducts innovative research on poxviruses.

April 26, 2013
Pictured: Jedd Wolchok
Combining Two FDA-Approved Drugs May Be Harmful for Patients with Metastatic Melanoma

Early research led by investigators at Memorial Sloan Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

April 4, 2013
Pictured: Steven Wang
Skin Cancer Expert Steven Wang Discusses FDA Sunscreen Label Changes

By mid-December 2012, sunscreen products on store shelves in the United States must meet stricter labeling regulations. Dr. Wang answers key questions on this topic.

December 17, 2012
Pictured: Paul Chapman
New England Journal of Medicine Case Study Reveals New Information about Advanced Melanoma Treatment

Memorial Sloan Kettering experts add to their knowledge of vemurafenib, a drug recently approved by the FDA to treat some patients with metastatic melanoma.

December 7, 2012
Pictured: Ping Chi
At Work: Physician-Scientist Ping Chi

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

November 2, 2012
Pictured: Patient James
James's Story about Melanoma

James had advanced melanoma and dwindling treatment options when his doctors enrolled him in a clinical trial of an innovative immunotherapy developed at Memorial Sloan Kettering.

October 15, 2012
Pictured: Paul Chapman
Investigational Treatment Shows Early Promise Against Metastatic Melanoma

Melanoma is an aggressive form of skin cancer that begins in the pigment-forming cells of the skin called melanocytes. While melanoma accounts for less than 5 percent of all skin cancers, it is far more serious than other skin cancers if not detected and treated early, before it has a chance to metastasize, or spread, to nearby lymph nodes and organs. Once the cancer has spread, the chances of achieving treatment success drop significantly. Recently, preliminary findings from a study led by Memorial Sloan Kettering investigators have revealed rapid and dramatic shrinking of metastatic tumors in patients treated with a new compound that interrupts a tumor-growth pathway present in the majority of patients with melanoma.

September 1, 2009
Pictured: Jedd Wolchok and James Allison
The New Yorker Features Immune Therapy Work of Memorial Sloan Kettering Researchers

In an article describing the history and promise of immunotherapy for cancer treatment, the magazine highlights the groundbreaking work of James Allison, Chair of the Sloan Kettering Institute’s Immunology Program, and medical oncologist and immunologist Jedd Wolchok.

April 20, 2012
Pictured: Jedd Wolchok
Rare Medical Phenomenon: Melanoma Patient’s Tumors Disappear throughout the Body after Radiation of One Tumor

Findings from a multidisciplinary research team led by Memorial Sloan Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

March 8, 2012
Pictured: David Solit
Study Reveals How Some Skin Tumors May Evade New Therapy

Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug vemurafenib.

March 1, 2012
Pictured: Memorial Sloan Kettering logo
Memorial Sloan Kettering Made Major Contributions to Cancer Advances in 2011

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

February 6, 2012
Memorial Sloan Kettering Researchers Appointed to Stand Up To Cancer Melanoma “Dream Team”

Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.

December 14, 2011
Pictured: Jedd Wolchok & Paul Chapman
Memorial Sloan Kettering Physician-Scientists Present Significant Clinical Cancer Research Advances at ASCO Annual Meeting

In an extraordinary demonstration of excellence, five Memorial Sloan Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.

July 1, 2011
James Allison
Immunotherapy Drug Receives FDA Approval for Advanced Melanoma

The US Food and Drug Administration announced in late March that the drug ipilimumab (Yervoy™) had been approved for the treatment of patients with metastatic melanoma.

July 1, 2011
Paul Chapman
New Targeted Therapy Shows Promise for Advanced Melanoma

A multicenter study led by Memorial Sloan Kettering Cancer Center investigators concluded that treatment with a new targeted therapy called PLX4032 resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

January 1, 2011

Related Media Coverage

Bristol-Myers Squibb: Big Pharma's Small Wonder

Melanoma and Immunotherapeutics Service Chief Jedd Wolchok commented on the immunotherapy drug ipilimumab (Yervoy™) for patients with advanced melanoma.

June 16, 2014
New System for Treating Cancer Seen as Hopeful

Melanoma and Immunotherapeutics Service Chief Jedd Wolchok shared his thoughts on updated research that shows that the effects of drug-based immunotherapy can sometimes last for years in patients who were treated for advanced melanoma.

June 3, 2014
Study Links Erectile Dysfunction Drugs with Increased Risk of Malignant Melanoma

Dermatology Service Chief Allan Halpern discussed a study that found a possible link between Viagra and an increased risk of developing melanoma.

April 10, 2014
Drug Is a First to Help Patients with Melanoma of the Eye

Medical oncologist Richard Carvajal discussed encouraging findings of a study he led that found that the experimental drug selumetinib is the first therapy able to improve progression-free survival and shrink tumors in patients with advanced uveal melanoma, a rare cancer of the eye.

June 1, 2013
Mole Misdiagnosis: When It's Really Stage IV Skin Cancer

Medical oncologist Mark Dickson and one of his patients spoke about metastatic melanoma.

May 17, 2013
Melanoma Treatment Uses Immune System to Kill Cancer Cells

Immunologist Jedd Wolchok discussed a study he led that used a combination of immunotherapy drugs to fight melanoma. The findings suggest that these two drugs may work better together than on their own.

May 15, 2013
Study Gives New Clues on Tumors

Medical oncologist Paul Chapman commented on a study that found a new genetic mutation in some melanoma patients.

January 25, 2013
Paul Chapman
New Targeted Therapy for Advanced Melanoma Associated with 80 Percent Response Rate

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.

August 25, 2010
Novel Genetic Mutation that Causes the Most Common form of Eye Cancer Discovered

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.

November 17, 2010
Novel Immunotherapy Drug Receives FDA Approval for the Treatment of Metastatic Melanoma

The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.

March 25, 2011